Cargando…
The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice
BACKGROUND: Cardiac steatosis is an early yet overlooked feature of diabetic cardiomyopathy. There is no available therapy to treat this condition. Tyrosine kinase inhibitors (TKIs) are used as first or second-line therapy in different types of cancer. In cancer patients with diabetes mellitus, TKIs...
Autores principales: | Gu, Yue, Avolio, Elisa, Alvino, Valeria V, Thomas, Anita C, Herman, Andrew, Miller, Poppy J, Sullivan, Niall, Faulkner, Ashton, Madeddu, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436421/ https://www.ncbi.nlm.nih.gov/pubmed/37592236 http://dx.doi.org/10.1186/s12933-023-01955-9 |
Ejemplares similares
-
Pulmonary hypertension with dasatinib and other tyrosine kinase
inhibitors
por: El-Dabh, Ashraf, et al.
Publicado: (2019) -
Personalized Cardiovascular Regenerative Medicine: Targeting the Extreme Stages of Life
por: Madeddu, Paolo, et al.
Publicado: (2019) -
The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation
por: Vandyke, K, et al.
Publicado: (2011) -
A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme
por: Nehoff, Hayley, et al.
Publicado: (2015) -
Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis
por: Guo, Kai, et al.
Publicado: (2019)